HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Mineralys Therapeutics, maintaining a price target of $30.
October 31, 2024 | 11:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Mineralys Therapeutics, maintaining a price target of $30.
The reiteration of a Buy rating and maintenance of a $30 price target by HC Wainwright & Co. is a positive signal for investors, suggesting confidence in the company's future performance. This could lead to increased investor interest and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100